By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / If you've been following ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

The woman was accused of selling counterfeit versions of popular weight loss drugs, including Ozempic and Wegovy. Experts say ...

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...